Knee Joint Injection

Evidence at a Glance

The knee is the most commonly injected major joint. Two distinct services share the same procedure codes: corticosteroid/anesthetic injection and viscosupplementation (intra-articular hyaluronic acid). The knee is the only joint for which hyaluronic acid is FDA-approved and payer-covered, and that coverage carries the most complex billing rules in this series: product-specific HCPCS codes, strict conservative-care and laterality requirements, series and six-month repeat rules, the EJ modifier, and - at many commercial payers - prior authorization. The evidence base for hyaluronic acid is under active review, and some payers are tightening coverage.

Domain	Summary
Medicare NCD	No national coverage determination. Corticosteroid injection is broadly covered; hyaluronic acid is governed by jurisdiction-specific MAC LCDs.
Medicare LCD / Article	Hyaluronan LCDs (for example L39260, L39529, L35427) set knee-OA criteria, conservative-care requirements, series definitions, and six-month repeat rules. Coverage is under evidentiary review and varies by MAC.
Commercial Coverage	Corticosteroid injection covered as medically necessary; hyaluronic acid covered for knee OA under criteria and frequently requires prior authorization as a medical-benefit drug.
Evidence Level	Corticosteroid: moderate short-term benefit. Hyaluronic acid: contested - society guidance (AAOS) does not recommend routine use, and recent reviews question efficacy, prompting payer tightening.
Image Guidance	Optional. The knee is accessible, so landmark injection (20610) is common. Ultrasound guidance is reported with 20611 (bundled); fluoroscopy with 20610 plus 77002.
Prior Authorization	Corticosteroid injection usually not authorized. Hyaluronic acid frequently requires prior authorization at commercial payers; Medicare applies LCD criteria without formal PA.
Conservative Therapy	Required for hyaluronic acid: documented failure of conservative measures (NSAIDs, physical therapy, analgesics, often prior corticosteroid) before a series.
Diagnostic Block	Not typically required. An anesthetic component can confirm the knee as the pain source within the same encounter.
Key Documentation	Symptomatic knee OA with laterality, conservative-care failure, product and regimen, series and interval history, guidance modality, and pre-/post pain scores.
Approval Considerations	Correct product-to-HCPCS mapping, laterality-specific OA diagnosis, documented conservative care, six-month interval compliance, and EJ modifier on series injections.

Procedure Overview

An intra-articular knee injection delivers medication into the knee joint to relieve pain and improve function, most commonly in osteoarthritis. Corticosteroid injection provides anti-inflammatory relief that is typically short-to-medium term. Viscosupplementation introduces hyaluronic acid to restore the viscoelastic properties of synovial fluid; its benefit is more variable and more contested. Because the knee is superficial and readily palpable, many injections are performed by landmark technique, with ultrasound guidance used selectively to confirm intra-articular placement or navigate difficult anatomy.

Operationally, the knee is where injection billing becomes genuinely complex. Viscosupplementation layers a specialty-drug billing structure on top of the injection: each product has its own HCPCS code, coverage is gated by conservative-care and laterality requirements, series are defined by FDA labeling, repeat series require a six-month interval and documented benefit, and commercial payers often require prior authorization. Getting paid depends on

managing the drug as much as the procedure.

Relevant Anatomy (High-Level)

The relevant anatomy is the tibiofemoral and patellofemoral compartments, the suprapatellar recess, and the accessible soft-tissue windows used for injection. The knee's superficial position and large synovial cavity make landmark injection reliable in most patients, which is why image guidance is optional rather than required. Osteoarthritic knees show cartilage loss and reduced hyaluronan concentration in synovial fluid, the rationale offered for viscosupplementation - a rationale that current evidence has increasingly called into question.

Clinical Indications

Symptomatic knee osteoarthritis with pain and functional limitation.
Inflammatory arthropathy or synovitis of the knee (corticosteroid).
Knee OA refractory to conservative care, as a candidate for viscosupplementation where covered.
Symptomatic joint effusion requiring aspiration, with or without concurrent injection.
Diagnostic confirmation of the knee as the pain source, in selected cases.

Patient Selection

Selection differs by injectate. Corticosteroid candidates have symptomatic knee pathology with a therapeutic goal. Viscosupplementation candidates must satisfy stricter coverage criteria:

Confirmed symptomatic knee osteoarthritis with laterality documented.
Documented failure of conservative measures (NSAIDs, physical therapy, analgesics, and often prior corticosteroid injection).
An FDA-approved product used per its labeled regimen.
For a repeat series, documented benefit from the prior series and at least six months since the last series.
Realistic expectations, including a candid discussion of the contested evidence for hyaluronic acid.

Contraindications

Absolute	Relative
Overlying skin/soft-tissue infection; suspected septic joint.	Therapeutic anticoagulation or coagulopathy (individualized).
Known allergy to the planned injectate (including avian-derived hyaluronic acid for some products).	Poorly controlled diabetes (corticosteroid glycemic effect).
Patient refusal or inability to cooperate.	Recent same-joint corticosteroid injection (cumulative risk).

Large tense effusion better managed by aspiration first.

Medical Necessity

Medical necessity for corticosteroid injection rests on symptomatic knee pathology and a therapeutic goal. Viscosupplementation carries a higher evidentiary bar that payers enforce closely:

A confirmed, laterality-specific knee osteoarthritis diagnosis the record supports.
Documented failure of conservative therapy before initiating a series.
The specific FDA-approved product and its labeled regimen.
Series and interval history, including documented benefit from any prior series and compliance with the six-month repeat interval.
The functional deficit treated and the therapeutic goal.

Medicare Coverage Guidance

Corticosteroid knee injection is covered when medically necessary under MAC joint-injection policy. Viscosupplementation is governed by jurisdiction-specific hyaluronan LCDs whose common requirements are:

Diagnosis. Symptomatic knee osteoarthritis coded to the M17 family with laterality; unspecified-laterality codes commonly trigger denial or review.
Conservative-care failure. Documented inadequate response to conservative non-pharmacologic therapy and simple analgesics or NSAIDs before a series.
FDA-labeled regimen. Dose and frequency consistent with the product's FDA labeling; regimens exceeding labeling are not covered.
Series and repeat rules. A series is the set of injections per joint per treatment per FDA labeling; a repeat series requires documented improvement and at least six months since the prior series.
Modifiers. The EJ modifier is appended to the drug code for subsequent injections in a series (not the first); JW/JZ modifiers report drug waste or its absence; RT/LT identify the knee.
Linkage. If the drug is denied as not reasonable and necessary, the associated injection code is also denied.

Commercial Payer Comparison

Payer / Program	Typical Posture on Knee Injection & Viscosupplementation
eviCore / Carelon / Cohere / Evolent	Corticosteroid injection generally not managed by interventional-pain UM; some plans route viscosupplementation through musculoskeletal or specialty-drug review.
Cigna	Corticosteroid injection covered; viscosupplementation covered for knee OA under criteria, subject to medical-benefit drug policy and, often, prior authorization.
Aetna	Considers corticosteroid injection medically necessary; covers hyaluronic acid for knee OA meeting criteria, with conservative-care and product requirements.
UnitedHealthcare	Routes hyaluronic acid products as commercial medical-benefit drugs (effective 2026) with coverage criteria; corticosteroid injection covered under medical policy.
Humana	Medicare Advantage aligns with MAC hyaluronan LCDs; commercial applies medical-necessity criteria and may require authorization for viscosupplementation.
Blue Cross Blue Shield plans	Plan-specific policies; viscosupplementation frequently prior-authorized with conservative-care and laterality requirements. Verify the local licensee policy.

Documentation Requirements

Symptomatic knee OA with laterality documented.
Conservative-care history and failure (for viscosupplementation).
Specific product name and FDA-labeled regimen.
Series number and date of prior series (for repeats).
Six-month interval compliance for repeat series.
Documented benefit from prior series (for repeats).
Guidance modality when used (landmark / ultrasound / fluoroscopy).
Injectate name, concentration, units; drug waste (JW/JZ).
Pre-injection numeric pain score.
Post-injection pain score and immediate percent relief.
Functional impairment and therapeutic goal.
Signed and dated procedure note.

Imaging Requirements

Diagnostic imaging (weight-bearing radiographs) establishes and grades knee osteoarthritis and supports the diagnosis required for coverage, particularly for viscosupplementation. Procedural guidance is optional for the knee because the joint is superficial and reliably accessible by landmark technique. When ultrasound guidance is used, report 20611 (guidance bundled, retained image required); when fluoroscopy is used, report 20610 with 77002. Image guidance should be selected on clinical grounds (difficult anatomy, obesity, prior surgery, need to confirm intra-articular placement) and documented accordingly, rather than applied routinely.

Prior Authorization Workflow

Benefit verification. Confirm coverage for corticosteroid injection and, separately, for the specific viscosupplementation product and whether prior authorization is required.
Conservative-care confirmation. Verify the documented conservative-care trial and failure satisfy the payer's requirement before initiating a series.
Diagnosis validation. Confirm a laterality-specific M17 knee-OA code the record supports; avoid unspecified-laterality codes.
Authorization (viscosupplementation). Submit the prior-authorization package (diagnosis, conservative-care failure, product and regimen, prior-series response) where required.
Product-to-code mapping. Map the specific product to its correct HCPCS code and confirm units and waste modifiers.
Procedure and coding. Report one unit of 20610/20611 per knee per encounter with laterality; append EJ to series injections after the first; append modifier 25 only for a separate E/M.
Post-service integrity. Ensure product, regimen, series interval, and pain scores are documented.

Common Prior Authorization & Claim Denials

Denial Reason	Root Cause / Prevention
Product-to-HCPCS mismatch	Wrong J-code for the product administered. Map each product to its specific HCPCS code; missing/incorrect codes are a leading viscosupplementation denial.
Unspecified-laterality diagnosis	M17.10 or M17.9 submitted. Use a laterality-specific M17 code (for example M17.11 / M17.12); unspecified codes trigger denial or review.
Conservative care not documented	Series initiated without documented conservative-care failure. Document the trial and outcome before the first injection.
Repeat series too soon	New series before six months elapsed, or without documented prior benefit. Confirm interval and response.
No prior authorization (viscosupplementation)	HA series billed without required commercial authorization. Obtain PA before scheduling.
Missing EJ modifier	Subsequent series injections billed without EJ. Append EJ to injections after the first in a series.
Regimen exceeds FDA labeling	Dose/frequency beyond labeling. Follow the product's FDA-approved regimen.
20610 billed when ultrasound was used	Ultrasound-guided injection must be reported with 20611. Map guidance to code.

Appeal Strategies

Submit the procedure note and drug documentation: product, regimen, series number, laterality, and pre-/post pain scores.
For conservative-care denials, attach the documented therapy trial and failure.
For repeat-series denials, document prior-series benefit and six-month interval compliance.
For product/code denials, confirm and correct the product-to-HCPCS mapping and units.
For laterality denials, correct to a laterality-specific M17 code the record supports.
Cite the applicable hyaluronan LCD/article or commercial policy establishing criteria were met; note that non-coverage on evidentiary grounds is not appealable on medical-necessity documentation alone.

Coding & Billing Overview

Applicable CPT® Codes

CPT®	Descriptor	Application
20610	Arthrocentesis, aspiration and/or injection; major joint or bursa, without ultrasound guidance	Landmark knee injection (corticosteroid or viscosupplementation).
20611	Same, with ultrasound guidance, with permanent recording and reporting	Ultrasound-guided knee injection; guidance bundled (do not add 76942).
77002	Fluoroscopic guidance for needle placement (add-on)	With 20610 when fluoroscopy is used (uncommon for the knee).
HCPCS - Viscosup	plementation Product Mapping (Illustrative)

HCPCS	Representative Product(s)	Note
J7318	Durolane	Single-dose; confirm units and waste (JW/JZ).
J7320	GenVisc 850	Multi-injection series.
J7321	Hyalgan / Supartz / Visco-3	Multiple products share this code.
J7323	Euflexxa	Multi-injection series.
J7324	Orthovisc	Multi-injection series.
J7325	Synvisc / Synvisc-One	Single- or multi-injection by product.
J7326	Gel-One	Single-injection.
J7327	Monovisc	Single-dose; carrier-judgment coverage.

Common ICD-10-CM Diagnosis Codes

Code	Description	Note
M17.11	Unilateral primary osteoarthritis, right knee	Right knee OA.
M17.12	Unilateral primary osteoarthritis, left knee	Left knee OA.
M17.0	Bilateral primary osteoarthritis of knee	Bilateral primary OA.
M17.31 / M17.32	Unilateral post-traumatic OA, right / left knee	Post-traumatic knee OA.
M17.10 / M17.9	Unilateral unspecified / OA knee unspecified	Often not accepted for viscosupplementation; avoid.
M25.561 / M25.562	Pain in right / left knee	When a specific diagnosis is not established.

Modifiers, POS & ASC

Element	Guidance
Modifier EJ	On the drug code for subsequent injections in a viscosupplementation series (not the first).
Modifier JW / JZ	JW for measurable drug waste; JZ when no waste (per payer requirement).
Modifier RT / LT	Identify the knee; Medicare uses RT and LT on separate lines for bilateral.
Modifier 50	For non-Medicare payers that require it for bilateral injection.
Modifier 25	For a significant, separately identifiable E/M (for example the decision to start a series after evaluation).
Place of Service	POS 11 (office) typical; POS 22 or 24 where applicable.

Clinical Documentation Checklist

Symptomatic knee OA with laterality.
Conservative-care failure (for viscosupplementation).
Product name and FDA-labeled regimen.
Series number and prior-series date.
Six-month interval and prior benefit (repeats).
Guidance modality (if used) and image retained.
Injectate name, units, waste (JW/JZ).
EJ modifier on series injections after the first.
Pre-injection numeric pain score.
Post-injection pain score and percent relief.
Laterality-specific M17 diagnosis.
Prior authorization on file (if required).

Procedure Comparison

Feature	Knee Corticosteroid	Knee Viscosupplementation	Hip Joint Injection
Typical CPT®	20610 / 20611	20610 / 20611 (+ HA J-code)	20610 (+77002) / 20611
Injectate coverage	Broadly covered	Covered (knee OA only)	Steroid covered; HA not covered
Guidance	Optional	Optional	Effectively required
Prior auth	Usually none	Often required (commercial)	Usually none
Series rules	Not applicable	Series + 6-month repeat	Not applicable
Coverage focus	Knee pathology	Laterality + conservative care + product	Hip pathology + guidance

GoHealthcare Clinical Insights

Manage the drug, not just the procedure. Knee viscosupplementation revenue is lost at the drug line far more often than the injection line. Build a product-to-HCPCS reference that pairs each product on the shelf with its code, units, and waste modifier, and reconcile it at each HCPCS update. Front-load the coverage gate. Conservative-care failure, laterality-specific diagnosis, and (for commercial plans) prior authorization must be established before the first injection of a series - not discovered when the second injection denies. Track the series like a clock. The six-month repeat interval and documented prior benefit are hard requirements. A simple series-and-interval tracker prevents the most common repeat-series denial.

GoHealthcare Leadership Perspective

Knee viscosupplementation is a specialty-drug program disguised as a minor injection. It carries drug acquisition cost, prior authorization, product-specific coding, series tracking, and a shifting evidence base - any of which can convert a well-intended service into a financial loss. Leadership should treat it with the rigor applied to buy-and-bill drugs, not the informality of an office injection. The priorities are a product-to-code reference maintained against HCPCS updates, a prior-authorization and conservative-care gate enforced before the first injection, a series-and-interval tracker, and periodic review of MAC and commercial coverage as the evidence and policies evolve. Where a payer has tightened or withdrawn coverage, the organization needs to know before, not after, it purchases and administers the drug.

GoHealthcare Prior Authorization Insight

The authorization insight is that knee injection splits cleanly into two risk profiles. Corticosteroid injection behaves like the other joint injections in this series: rarely authorized, governed by documentation and frequency. Viscosupplementation behaves like a specialty drug: frequently prior-authorized commercially, gated by conservative care and laterality, and exposed to a contracting evidence base. Our quality-assurance approach verifies the drug pathway before the clinical one: confirm product coverage and authorization, confirm conservative-care documentation and diagnosis laterality, confirm series interval and prior benefit, and confirm product-to-code mapping. Only then does the series proceed. This prevents the drug-line denials and repeat-series denials that define viscosupplementation losses.

GoHealthcare Case Study

The following case is a composite created for education. It does not depict any actual patient or organization.

Clinical Scenario

A practice initiated a five-injection viscosupplementation series for a patient with right knee osteoarthritis who had failed physical therapy and NSAIDs. The first injection paid; the subsequent injections denied.

Documentation & Coding Challenges

Review found three problems: the subsequent injections lacked the EJ modifier on the drug code; the diagnosis had been entered as unspecified-laterality knee OA on several claims; and the commercial plan required prior authorization for the product, which had not been obtained. A separate patient's series denied because the product billed did not match the HCPCS code submitted.

Payer & Prior Authorization Barriers

The practice had treated viscosupplementation like a routine injection rather than a specialty-drug program, so neither the authorization nor the product-to-code mapping had been verified before the series began.

Resolution Strategy

The practice obtained retrospective authorization where allowed, corrected the laterality and EJ-modifier errors, and reconciled the product-to-HCPCS mapping. Prospectively, it implemented a viscosupplementation intake checklist (authorization, conservative care, laterality, product mapping, series interval) completed before the first injection.

Outcome & Lessons Learned

Recoverable claims were paid on appeal, and viscosupplementation denials fell sharply once the intake checklist was enforced. The lesson: knee viscosupplementation must be run as a specialty-drug program with a front-end gate, not as an office injection billed after the fact.

GoHealthcare Best Practices

Maintain a product-to-HCPCS reference (code, units, waste modifier) reconciled at each HCPCS update.
Enforce a viscosupplementation intake gate before the first injection: authorization, conservative care, laterality, product mapping, series interval.
Use laterality-specific M17 diagnoses; block unspecified-laterality codes for viscosupplementation.
Append EJ to series injections after the first, and JW/JZ for drug waste.
Track series number, product, and six-month intervals per knee.
Review MAC and commercial hyaluronan coverage periodically as the evidence base evolves.

Common Mistakes

Billing the wrong HCPCS code for the product administered.
Using an unspecified-laterality knee-OA diagnosis for viscosupplementation.
Initiating a series without documented conservative-care failure.
Starting a repeat series before six months or without documented prior benefit.
Omitting the EJ modifier on subsequent series injections.
Failing to obtain required commercial prior authorization for the product.
Exceeding the FDA-labeled dose or frequency.
Reporting 20610 plus 76942 for an ultrasound-guided injection instead of 20611.

Pearls and Pitfalls

Pearls	Pitfalls
Pair each product with its HCPCS code at the point of purchase.	Assuming one J-code fits all hyaluronic acid products.
Gate the series before the first injection.	Discovering the authorization gap at the second injection.
Code knee-OA laterality precisely.	Defaulting to unspecified-laterality codes.
Track the six-month clock per knee.	Starting a repeat series too soon.
Append EJ to series injections after the first.	Omitting EJ and triggering series denials.

Frequently Asked Questions

What CPT code is used for a knee injection?

20610 (without ultrasound) or 20611 (with ultrasound guidance). The knee is a major joint and is commonly injected by landmark technique.

Is image guidance required for the knee?

No. The knee is superficial and reliably accessible by landmark technique. Use 20611 only when ultrasound guidance is performed and documented.

Is hyaluronic acid covered for the knee?

Yes. The knee is the only joint for which hyaluronic acid is FDA-approved and payer-covered, under specific criteria that include documented conservative-care failure and a laterality-specific diagnosis.

Does viscosupplementation require prior authorization?

Often, at commercial payers, where it is treated as a medical-benefit specialty drug. Medicare Part B does not require formal PA but enforces LCD criteria.

How do I code the hyaluronic acid product?

Each product maps to a specific HCPCS code (for example J7321, J7323, J7325, J7327, among others). Verify the exact product and its current code; mismatches are a leading denial.

What is the EJ modifier for?

It is appended to the drug code for subsequent injections in a series, not the first. Omitting it causes series denials.

What ICD-10 codes support viscosupplementation?

Laterality-specific knee-OA codes such as M17.11 (right) and M17.12 (left), and post-traumatic equivalents. Unspecified-laterality codes are commonly denied.

Why did my second and third injections deny?

Common causes are a missing EJ modifier, an unspecified-laterality diagnosis, or missing prior authorization for the product.

How often can a viscosupplementation series be repeated?

A repeat series generally requires at least six months since the prior series and documented improvement from it.

What conservative care is required first?

Documented failure of conservative measures such as NSAIDs, physical therapy, and analgesics, often including prior corticosteroid injection, before a series.

Can I bill corticosteroid and hyaluronic acid together?

They are distinct services with distinct coverage. Follow payer rules; when additional substances are administered with viscosupplementation, only one injection service is allowed per knee.

How many units of 20610/20611 per knee?

One unit per knee per encounter, even if aspiration and injection are both performed.

How is bilateral knee injection reported?

Medicare reports RT on one line and LT on a second; non-Medicare payers may require modifier 50.

What are JW and JZ modifiers?

JW reports measurable drug waste from a vial; JZ attests no waste. Apply per payer requirement, especially for single-dose products.

Is hyaluronic acid still recommended for knee OA?

Its use is contested. Society guidance (AAOS) does not recommend routine use, and some payers have tightened coverage. Verify current policy and set patient expectations accordingly.

What happens if the drug denies?

If the drug is denied as not reasonable and necessary, the associated injection code is also denied. Verify coverage and mapping before administering.

Can I bill an E/M with the injection?

Only for a significant, separately identifiable evaluation - for example the decision to start a series after evaluation - with modifier 25.

What place of service applies?

POS 11 (office) is typical; POS 22 or 24 where applicable.

Do I need imaging to diagnose knee OA for coverage?

Weight-bearing radiographs commonly support the diagnosis and grade of OA, which strengthens medical necessity for viscosupplementation.

What single control most reduces knee-injection denials?

A viscosupplementation intake gate completed before the first injection: authorization, conservative care, laterality, and product-to-code mapping.

Can aspiration and injection both be billed?

They are reported as a single unit of 20610/20611 when performed at the same session on the same joint.

Does Medicare Advantage cover viscosupplementation?

Most plans do, but copays, prior authorization, and network rules vary; verify the specific plan.

Key Takeaways

Knee injection uses 20610/20611; guidance is optional because the knee is accessible.
The knee is the only joint where hyaluronic acid is covered - under strict criteria.
Map each viscosupplementation product to its specific HCPCS code; mismatches deny.
Use laterality-specific M17 codes; unspecified laterality is commonly denied.
Document conservative-care failure before a series and honor the six-month repeat rule.
Append EJ to series injections after the first; apply JW/JZ for drug waste.
Assume commercial prior authorization for viscosupplementation until verified.
Hyaluronic-acid evidence and coverage are tightening; verify current policy.

Future Outlook

The most consequential trend for knee injection is the contraction of viscosupplementation coverage. As society guidance declines to recommend routine hyaluronic acid and systematic reviews question its efficacy, MACs and commercial payers are re-examining and, in some jurisdictions, restricting coverage. Practices should expect continued policy volatility and manage viscosupplementation as a specialty-drug program with disciplined intake, product mapping, and coverage surveillance. Corticosteroid knee injection will remain a stable, covered service. Ultrasound guidance will remain optional but increasingly available, useful in difficult anatomy and for confirming placement.

References

Centers for Medicare & Medicaid Services. LCD - Hyaluronic Acid Injections for Knee Osteoarthritis (L39260). https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=39260

Centers for Medicare & Medicaid Services. LCD - Intraarticular Knee Injections of Hyaluronan (L39529). https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?LCDId=39529 Centers for Medicare & Medicaid Services. Billing and Coding: Intraarticular Knee Injections of Hyaluronan (A56157). https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=56157 American Medical Association. CPT® 2026 Professional Edition (20610, 20611, 77002). https://www.ama-assn.org/practice-management/cpt AAPC. Sticking Points for Hyaluronic Acid Knee Injection Claims (laterality, product-to-code mapping). https://www.aapc.com/blog/93351-sticking-points-for-hyaluronic-acid-knee-injection-claims/UnitedHealthcare. Sodium Hyaluronate - Commercial Medical Benefit Drug Policy (2026). https://www.uhcprovider.com/content/dam/provider/docs/public/policies/comm-medical-drug/sodium-hyaluronate.pdf ICD-10-CM 2026, M17.- (Osteoarthritis of knee). https://www.icd10data.com/ICD10CM/Codes/M00-M99/M15-M19/M17-American Academy of Orthopaedic Surgeons (AAOS). Management of Osteoarthritis of the Knee (Non-Arthroplasty) Clinical Practice Guideline. https://www.aaos.org American College of Rheumatology (ACR) osteoarthritis management guidance. https://rheumatology.org

Reading Recommendations

Your MAC's hyaluronan LCD and billing article, including current coverage status and covered diagnosis list.
Commercial viscosupplementation medical-benefit drug policies and prior-authorization criteria for your top payers.
Current HCPCS product-to-code updates for hyaluronic acid products.
AAOS and ACR osteoarthritis management guidelines.

Recommended Downloads

Viscosupplementation Intake Checklist (authorization, conservative care, laterality, product mapping, series interval).
Product-to-HCPCS Mapping Worksheet (reconciled to current HCPCS).
Series-and-Interval Tracking Worksheet (per knee).
Knee Injection Structured Procedure Note Template.

Visual Recommendations

High-level illustration of the knee joint and injection windows.
Corticosteroid-versus-viscosupplementation decision and coverage flow.
Viscosupplementation intake-gate process map.
Product-to-HCPCS mapping matrix.
Series-and-interval timeline (six-month repeat rule).
Laterality-specific diagnosis quick-reference infographic.

Educational Disclaimer

This document is intended for educational and operational reference purposes only. It does not replace physician clinical judgment, payer policy review, legal advice, or official CMS guidance, and it is not a procedural or physician training manual. Coverage policies, coding guidance, product-to-code mappings, frequency limitations, and reimbursement requirements change frequently and vary by payer, plan, and jurisdiction; all codes and coverage criteria must be independently verified against the applicable payer policy and current regulatory sources before submission. CPT® is a registered trademark of the American Medical Association. GoHealthcare Practice Solutions assumes no liability for actions taken in reliance on this educational material.

This webpage does not replace physician judgment, official payer policy, legal advice, or current coding guidance. CPT® is a registered trademark of the American Medical Association.